News Focus
News Focus
Followers 99
Posts 13186
Boards Moderated 0
Alias Born 06/01/2013

Re: bow-tie post# 21544

Tuesday, 12/01/2020 12:17:45 AM

Tuesday, December 01, 2020 12:17:45 AM

Post# of 27661
Is Roche's latest Tecentriq win really a win for Merck's Keytruda?

https://www.fiercepharma.com/marketing/roche-s-latest-tecentriq-win-really-a-win-for-merck-s-keytruda

Anti-PD-1 monotherapy or PD-L1/PD-1 inhibitors in combination with platinum-based doublet chemotherapy, with or without Avastin (bevacizumab) are first-line standards of care in metastatic NSCLC. Merck’s Keytruda,

https://www.pharmaceutical-technology.com/comment/esmo-2019-roches-tecentriq/

FDA Approves Tecentriq (Atezolizumab) for Small Cell Lung Cancer

https://www.cancer.org/latest-news/fda-approves-tecentriq-atezolizumab-for-small-cell-lung-cancer.html

On Tuesday, February 14, 2012, Roche and its U.S. biotech unit Genentech announced that counterfeit Avastin had been distributed in the United States.

https://en.wikipedia.org/wiki/Bevacizumab#:~:text=Bevacizumab%2C%20sold%20under%20the%20brand,%2C%20and%20renal%2Dcell%20carcinoma.

Seems big pharma has a learning problem

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y